Rivoceranib is a selective potent inhibitor of vascular endothelial growth factor receptor-2 (known as VEGFR2) which mediates the primary pathway for tumor-mediated angiogenesis. Rivoceranib is a low-molecular inhibitor that is highly regarded as the best-in-class drug due to its high VEGRF-2 selectivity and fewer side effects.
Apealea® is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen).Apealea® is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment. Apealea® contains the active substance paclitaxel.
2825 E Cottonwood Pkwy Suite 180,Salt Lake City, UT 84121 U.S.A.Tel
400 Oyster Point Blvd, Suite 214, South San Francisco, CA 94080 U.S.A.